Documents released in November 2021 by the U.S. Food and Drug Administration (FDA) as part of a court-mandated information dump reveal that enrollment at one particular trial site happened at warp speed, just in time to meet the safety deadline for the FDA's VRBPAC meeting on Dec. 10, 2020.
This meeting is where the FDA discussed granting Emergency Use Authorization (EUA) for the Pfizer-BioNTech injection in people 16 years of age and older. (Related: The contents of the Pfizer jab were recently shown to "stick" to bodily organs.)
"The allegedly suspicious-looking clinical trial data surrounds 'the biggest recruiter by far,' site 1231 (site 4444 was assigned site id 1231) in Argentina," reported Undercover DC.
"Adding to the confusion, in five short days before the safety deadline (including a Sunday, 9/27/20), the trial recruited 1,275 of the 4,501 people using site number 4444. In just three weeks, the site recruited 4,501 patients – 10% of the entire trial at one site."
"Overall, Pfizer rapidly recruited roughly 44,000 people for their trial, which took place at 152 locations worldwide and was overseen by numerous investigators, including Dr. Fernando Polack, who led the Argentinian study at Hospital Militar Central."
Polack, as explained by investigative reporter Steve Kirsch, holds the position of Scientific Director at the INFANT Foundation in Buenos Aires. This Vanderbilt-affiliated foundation facilitates biomedical translational research and pediatric rotations at hospitals and medical centers throughout the city.
Polack personally coordinates 26 hospitals in Argentina involving 467 doctors who were all immediately recruited into the Pfizer trial. Kirsch says that on paper, the data that resulted "looks too good to be true," though he says "it's quite possible they pulled it off" by coordinating the trial in record time.
"So if all 26 hospitals participated fully then that's 57 patients per week per hospital which is possible if the sites have done this before and have a coordination framework for getting all 26 sites up and running at the same time," Kirsch writes. "This means that everyone who was doing something else dropped what they were doing to switch over to the trial all at the same time."
Prof. Norman Fenton from Queen Mary University of London added in his own two-part Substack series that what was supposedly pulled off in Argentina on behalf of Pfizer is "basically impossible."
"[I]f this really happened," he wrote, "it would be a wonder of the world, and they should publish the process with pride and win 27 different prizes for it."
"They claim to have enrolled seven days a week for three weeks with zero gaps. Each patient requires a 250-page case report form," Fenton added. "The lead investigator seems to have been Fernando Polack."
"If indeed, the best way to get things done is to give them to busy people, then this was a great choice because, from the look of things, Fernando is one busy fellah and connected up the wazoo to boot. He also works with Vanderbilt, the FDA, and the Infant Foundation, funded by the Gates Foundation and the NIH."
In the disclosure forms associated with a New England Journal of Medicine (NEJM) paper on Pfizer's injection, Polack's conflicts of interest are revealed. They show personal fees he accepted from not only Pfizer but also Janssen (Johnson & Johnson), Regeneron (monoclonal antibodies), Merck & Co. and Novavax.
Should any of this make it to court, Pfizer will be in a whole lot of trouble – and rightfully so. Perhaps justice will eventually prevail.
More related news about Pfizer can be found at PharmaceuticalFraud.com.
Sources for this article include: